Alkermes (ALKS) Stock Price, News & Analysis

Company Overview

Alkermes plc (NASDAQ: ALKS) is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system diseases. Its research and development activities include treatments for schizophrenia, bipolar disorder, addiction and other serious neurological or psychiatric conditions, with an emphasis on long-acting injectable and extended-release formulations.

The company’s marketed products include VIVITROL, an extended-release injectable form of naltrexone used to treat alcohol dependence and prevent relapse to opioid dependence after detoxification; ARISTADA, an extended-release injectable formulation of aripiprazole lauroxil for the treatment of schizophrenia in adults; and LYBALVI, an oral combination of olanzapine and samidorphan approved for schizophrenia and bipolar I disorder in adults.

Founded in Ireland in 1987, Alkermes has developed drug-delivery technologies intended to help extend dosing intervals and support medication adherence. The company is headquartered in Waltham, Massachusetts, and maintains operations in the United States and Ireland. Its medicines are primarily commercialized in the U.S., with certain products and rights supported through commercial partners in other markets.

Key Stats

• Today's Range: $45.73 to $46.75
• 50-Day Range: $45.40 to $55.22
• 52-Week Range: $26.40 to $55.67
• Volume: 1.28 million shs
• Average Volume: 1.21 million shs
• Market Capitalization: $7.71 billion
• P/E Ratio: 120.98
• Dividend Yield: N/A
• Price Target: $54.56
• Consensus Rating: Moderate Buy

Alkermes Stock Analysis - MarketRank™

Alkermes scored higher than 58% of companies evaluated by MarketBeat, and ranked 430th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.72, and is based on 1 strong buy rating, 12 buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

Alkermes has a consensus price target of $54.56, representing about 18.7% upside from its current price of $45.97.

Amount of Analyst Coverage

Alkermes has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alkermes are expected to grow in the coming year, from ($0.56) to $0.24 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alkermes is 120.98, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.90.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alkermes is 120.98, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.94.

Price to Book Value per Share Ratio

Alkermes has a P/B Ratio of 4.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.19% of the float of Alkermes has been sold short.

Short Interest Ratio / Days to Cover

Alkermes has a short interest ratio ("days to cover") of 11.79, which indicates bearish sentiment.

Change versus previous month

Short interest in Alkermes has recently decreased by 0.30%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alkermes does not currently pay a dividend.

Dividend Growth

Alkermes does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 1.09

News Sentiment

Alkermes has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Alkermes this week, compared to 6 articles on an average week.

Search Interest

Only 4 people have searched for ALKS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Alkermes to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Alkermes insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,242,213.00 in company stock.

Percentage Held by Insiders

4.59% of the stock of Alkermes is held by insiders.

Percentage Held by Institutions

95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 2/26/2026
• Today: 9/13/2026
• Next Earnings (Estimated): 10/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ALKS
• CIK: 1520262
• Web: www.alkermes.com
• Phone: (531) 772-8000
• Fax: 781-890-0524
• Employees: 2,050
• Year Founded: 1987

Price Target and Rating

• Average Price Target for Alkermes: $54.56
• High Price Target: $65.00
• Low Price Target: $36.00
• Potential Upside/Downside: +18.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.72
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.38
• Trailing P/E Ratio: 120.98
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $241.66 million
• Net Margins: 3.96%
• Pretax Margin: 5.84%
• Return on Equity: 4.15%
• Return on Assets: 2.19%

Debt

• Debt-to-Equity Ratio: 0.82
• Current Ratio: 2.30
• Quick Ratio: 1.85

Sales & Book Value

• Annual Sales: $1.48 billion
• Price / Sales: 5.23
• Cash Flow: $1.67 per share
• Price / Cash Flow: 27.46
• Book Value: $11.02 per share
• Price / Book: 4.17

Miscellaneous

• Outstanding Shares: 167,760,000
• Free Float: 160,063,000
• Market Cap: $7.71 billion
• Optionable: Optionable
• Beta: 0.31